Compare 10X Genomics Inc (TXG) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Exxon Mobil Corporation — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Exxon Mobil Corporation trades at $164.53 (market cap $660.62B). The key difference: Exxon Mobil Corporation is far larger — about 77.3× 10X Genomics Inc's market cap, and Exxon Mobil Corporation pays a 2.56% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | XOM | |
|---|---|---|
Market Cap | $8.55B | $660.62B |
Sector | Health | Energy |
52-Week High | $67.29 | $171.52 |
52-Week Low | $11.34 | $110.64 |
Enterprise Value | $8.08B | $692.40B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
ExxonMobil (XOM) trades at $164.26, up 3.01% today, with a neutral technical signal and bullish moving averages. The stock shows solid profitability with a 9.07% net margin and 12.55% ROE, though revenue and net income have declined from 2022 peaks. Recent earnings beat estimates in two of the last three quarters, with Q3 2026 results pending. Analyst consensus is a $168.14 price target, with 39% buy ratings. News highlights Exxon's Permian Basin strength and warnings of potential oil price spikes to $160.
XOM offers value with a P/E of 20.68 and strong cash flow, but faces risks from volatile oil prices and declining margins. The dividend provides income, yet geopolitical tensions and energy transition pressures pose challenges. Upside depends on execution in the Permian and oil market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
